Finally, we performed RNAseq experiments aimed to determine downstream effectors of STYK1 in NSCLC cells and to unravel the underlying mechanisms sustaining the potentiation of the combined treatment with EGFR inhibitors and knockdown of STYK1. The gene discussed is STYK1; the disease is non-small cell lung carcinoma.